Clareo Health | Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)
Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ViiV Healthcare
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults (greater than or equal to \[\>=\]18 years old) at the time of signing the informed consent.
HIV-1 infected and have been prescribed CABNEUVA per the United States Prescribing information (USPI).
Participants can be enrolled
If they have been taking oral VOCABRIA + EDURANT or other ART for approximately 1 month (at least 28 days) prior to Baseline/Month 1, or
Already taking CABENUVA prior to Baseline/Month 1 and the last injections were within a 1 month +/- 7-day window or for every 2-month injections, the timing will vary if they are receiving the initiation injections (1 month +/- 7-day) or the continuation injections (2 months +/- 7 days) per the USPI, or
Prescribed direct to inject and receive their 1st injection without an oral lead in at the Infusion Center/ASA on the last day of any other antiretroviral therapy
Agreement to receive CABENUVA IM injections at participating infusion center/ASA.
You may not be if
Participants are excluded from the study as dictated in the Prescribing Information (CABENUVA \[USPI\]) in consultation with the HIV care provider.
Contraindications, as per the current Prescribing Information \[CABENUVA USPI\]
New health condition / prohibited medication reported - Other Reason at the discretion of the HIV care provider or IC/ ASA staff
